News

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...
The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...
Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.
The US drug regulator has missed a deadline for granting full approval to Novavax's COVID-19 vaccine, the company said ...
The US Food and Drug Administration was supposed to make a final decision about whether or not to approve Novavax's (NVAX) ...
Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.
The US Food and Drug Administration was supposed to make a final decision about whether or not to approve Novavax's (NVAX) COVID-19 vaccine this week, but that deadline has passed with no clarity ...
The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...
Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.
The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. HealthDay News — The US Food and Drug Administration (FDA) has delayed the full ...